Saonfi (SNY) to End Work at Toulouse Site
Tweet Send to a Friend
Up)
Saonfi (NYSE: SNY) shares are flat in pre-market action Thursday following affirmation from an employee that the French pharma giant is planning to halt research in Toulouse.
According to Bloomberg, Sanofi researcher Marc Bianciotto issued comments in an interview earlier. He said Sanofi's head of research Elias Zerhouni met with employees at the location today to tell them the news.
On July 5th, Sanofi said all options remain for the site. Sanofi announced 2,000 job cuts the same day.
Toulouse was the location were the ground-breaking blood thinner Plavix was developed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
According to Bloomberg, Sanofi researcher Marc Bianciotto issued comments in an interview earlier. He said Sanofi's head of research Elias Zerhouni met with employees at the location today to tell them the news.
On July 5th, Sanofi said all options remain for the site. Sanofi announced 2,000 job cuts the same day.
Toulouse was the location were the ground-breaking blood thinner Plavix was developed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
- Rockwell Medical (RMTI) Closes $20M Debt Financing
- Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Layoffs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
